Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: August 2015

5 - Choosing appropriate patients for anticoagulation

1.Eikelboom, JW, Connolly, SJ, Brueckmann, M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206–14.
2.Mischie, AN, Chioncel, V, Droc, I, Sinescu, C. Anticoagulation in patients with dilated cardiomyopathy, low ejection fraction, and sinus rhythm: back to the drawing board. Cardiovasc Ther 2013;31(5):298–302.
3.Massie, BM, Krol, WF, Ammon, SE. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004;10(2):101–12.
4.Pullicino, PM, Thompson, JL, Sacco, RL, et al. Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. Cerebrovasc. Dis. Basel Switz 2013; 36:74–8.
5.January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation; published online March 28, 2014.
6.Diener, HC, Eikelboom, J, Connolly, SJ, et al. AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012;11(3):225–31.
7.Healey, , J. A Comparison of Apixaban Versus Aspirin for Preventing Stroke in Patients With Pacemakers (ARTESiA). NCT01938248. (2013). At http://clinicaltrials.gov/show/NCT01938248.
8.Granger, CB et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.
9.Connolly, SJ, Ezekowitz, MD, Yusuf, S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
10.US FDA. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. (2014). At www.fda.gov/Drugs/DrugSafety/ucm396470.htm.
11.Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
12.Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
13.Skjoth, F, Larsen, TB, Rasmussen, LH, Lip, GYH. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111:981–8.
14.Lip, GY, Manning, WJ, Weissman, NJ. Left ventricular thrombus after acute myocardial infarction. (2014). At www.uptodate.com/contents/left-ventricular-thrombus-after-acute-myocardial-infarction.
15.Shacham, Y, Leshem-Rubinow, E, Ben Assa, E, et al. Frequency and correlates of early left ventricular thrombus formation following anterior wall acute myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2013;111:667–70.
16.Buss, NI, Friedman, SE, Andrus, BW, DeVries, JT. Warfarin for stroke prevention following anterior ST-elevation myocardial infarction. Coron Artery Dis 2013;24:636641.
17.Charidimo, A, Shakeshaft, C, Werring, DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol 2012;3:133. eCollection 2012.